Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing innovative biologic therapies to treat retinal diseases, today announced positive data from the Phase 1b dose escalation study of OPT-302 for patients with diabetic macular edema (DME).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,